Sanctura XR

See also: Generic Sanctura

Sanctura XR is a brand name of trospium, approved by the FDA in the following formulation(s):

SANCTURA XR (trospium chloride - capsule, extended release; oral)

• 
  Manufacturer: ALLERGAN
  
  Approval date: August 3, 2007
  
  Strength(s): 60MG ^[RLD]

Has a generic version of Sanctura XR been approved?

No. There is currently no therapeutically equivalent version of Sanctura XR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sanctura XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Once daily dosage forms of trospium
  Patent 7,410,978
  Issued: August 12, 2008
  Inventor(s): Kidane; Argaw & Flanner; Henry H. & Bhatt; Padmanabh & Raoufinia; Arash
  Assignee(s): Supernus Pharmaceuticals, Inc.
  A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
  
  Patent expiration dates:
  
  
  • February 1, 2025
    
    ✓ 
    Drug product
  
  



• 
  Method of treating bladder dysfunction with once-a-day trospium salt formulation
  Patent 7,759,359
  Issued: July 20, 2010
  Inventor(s): Kidane; Argaw & Flanner; Henry H. & Bhatt; Padmanabh & Raoufinia; Arash
  Assignee(s): Supernus Pharmaceuticals, Inc.
  A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
  
  Patent expiration dates:
  
  
  • November 4, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
  
  



• 
  Once daily dosage forms of trospium
  Patent 7,763,635
  Issued: July 27, 2010
  Inventor(s): Kidane; Argaw & Flanner; Henry H. & Bhatt; Padmanabh & Raoufinia; Arash
  Assignee(s): Supermus Pharmaceuticals, Inc.
  A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
  
  Patent expiration dates:
  
  
  • November 4, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
  
  



• 
  Once daily dosage forms of trospium
  Patent 7,781,448
  Issued: August 24, 2010
  Inventor(s): Kidane; Argaw & Flanner; Henry H. & Bhatt; Padmanabh & Raoufinia; Arash
  Assignee(s): Supernus Pharmaceuticals, Inc.
  A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
  
  Patent expiration dates:
  
  
  • November 4, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
  
  



• 
  Trospium chloride treatment method
  Patent 7,781,449
  Issued: August 24, 2010
  Inventor(s): Kidane; Argaw & Flanner; Henry H. & Bhatt; Padmanabh & Raoufinia; Arash
  Assignee(s): Supernus Pharmaceuticals, Inc.
  A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
  
  Patent expiration dates:
  
  
  • November 4, 2024
    
    ✓ 
    Patent use: METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 3, 2010 - NEW DOSAGE FORM
  
  

See also...

• Sanctura XR Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Sanctura XR Consumer Information (Cerner Multum)
• Trospium Consumer Information (Wolters Kluwer)
• Trospium Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Trospium Consumer Information (Cerner Multum)
• Trospium Advanced Consumer Information (Micromedex)
• Trospium Chloride AHFS DI Monographs (ASHP)